비낭포성 섬유증 기관지확장증 시장 : 세계 산업 규모, 점유율, 동향, 기회 및 예측 - 치료별, 진단별, 최종 용도별, 지역별, 경쟁별 세분화(2020-2030년)

The Global Non-Cystic Fibrosis Bronchiectasis Market, valued at USD 3.71 Billion in 2024, is projected to experience a CAGR of 5.30% to reach USD 5.06 Billion by 2030. The Global Non-Cystic Fibrosis Bronchiectasis (NCFB) market addresses a chronic lung condition characterized by the permanent dilation and thickening of the airways, distinct from cystic fibrosis, which leads to impaired mucus clearance and recurrent respiratory infections. The market is primarily driven by the increasing global prevalence of chronic respiratory diseases, alongside significant advancements in diagnostic technologies, such as high-resolution CT scans, facilitating earlier and more accurate disease identification.

Key Market Drivers

The increasing global prevalence of non-cystic fibrosis bronchiectasis (NCFB) stands as a primary market driver, directly raising demand for diagnostic and therapeutic resources. This trend is fueled by advancements in diagnostic technologies, heightened clinician awareness, and a deeper understanding of NCFB's diverse etiologies. NCFB's chronic and progressive nature, often involving recurrent infections, necessitates continuous medical management. As diagnostic methods become more precise, leading to earlier identification, recorded prevalence rates steadily increase.

Key Market Challenges

The limited availability of specific, disease-modifying therapies for Non-Cystic Fibrosis Bronchiectasis significantly constrains market expansion. Current treatment approaches predominantly focus on managing symptoms and complications, such as recurrent infections, rather than addressing the underlying disease progression. This reliance on symptomatic or off-label treatments creates a substantial unmet medical need and restricts the development of a dedicated market segment for truly transformative interventions. Pharmaceutical companies face reduced incentives for significant investment in a therapeutic area where targets for disease modification are not well-defined or approved pathways are limited.

Key Market Trends

The development of disease-modifying and biologic therapies signifies a pivotal evolution in the Global Non-Cystic Fibrosis Bronchiectasis Market, shifting beyond symptomatic management to interventions that directly alter disease progression. This focus includes advanced biologic agents and small molecules designed to reduce inflammation or disrupt bacterial colonization. According to the American Thoracic Society (ATS) 2025 International Conference, in May 2025, the average initial hospitalization for NCFBE patients was 7.1 days, costing 22,355 USD, highlighting the substantial burden new treatments aim to alleviate.

Key Market Players

• Novartis AG
• Pfizer Inc.
• Bayer AG
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• GSK plc
• F. Hoffmann-La Roche Ltd.
• Sun Pharmaceutical Industries Ltd.
• Aurobindo Pharma Ltd.
• Dr. Reddy's Laboratories Ltd.

Report Scope:

In this report, the Global Non-Cystic Fibrosis Bronchiectasis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Non-Cystic Fibrosis Bronchiectasis Market, By Treatment:

• Surgery
• Physiotherapy
• Vaccination
• Airway pharmacotherapy
• Antibiotics
• Others

Non-Cystic Fibrosis Bronchiectasis Market, By Diagnosis:

• CT scan
• Bronchoscopy
• Chest X-ray
• Lung function
• Sputum culture test
• Blood tests
• Others

Non-Cystic Fibrosis Bronchiectasis Market, By End use:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Non-Cystic Fibrosis Bronchiectasis Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Non-Cystic Fibrosis Bronchiectasis Market.

Available Customizations:

Global Non-Cystic Fibrosis Bronchiectasis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Non-Cystic Fibrosis Bronchiectasis Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment (Surgery, Physiotherapy, Vaccination, Airway pharmacotherapy, Antibiotics, Others)
  • 5.2.2. By Diagnosis (CT scan, Bronchoscopy, Chest X-ray, Lung function, Sputum culture test, Blood tests, Others)
  • 5.2.3. By End use (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Non-Cystic Fibrosis Bronchiectasis Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment
  • 6.2.2. By Diagnosis
  • 6.2.3. By End use
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment
      • 6.3.1.2.2. By Diagnosis
      • 6.3.1.2.3. By End use
  • 6.3.2. Canada Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment
      • 6.3.2.2.2. By Diagnosis
      • 6.3.2.2.3. By End use
  • 6.3.3. Mexico Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment
      • 6.3.3.2.2. By Diagnosis
      • 6.3.3.2.3. By End use

7. Europe Non-Cystic Fibrosis Bronchiectasis Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment
  • 7.2.2. By Diagnosis
  • 7.2.3. By End use
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment
      • 7.3.1.2.2. By Diagnosis
      • 7.3.1.2.3. By End use
  • 7.3.2. France Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment
      • 7.3.2.2.2. By Diagnosis
      • 7.3.2.2.3. By End use
  • 7.3.3. United Kingdom Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment
      • 7.3.3.2.2. By Diagnosis
      • 7.3.3.2.3. By End use
  • 7.3.4. Italy Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment
      • 7.3.4.2.2. By Diagnosis
      • 7.3.4.2.3. By End use
  • 7.3.5. Spain Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment
      • 7.3.5.2.2. By Diagnosis
      • 7.3.5.2.3. By End use

8. Asia Pacific Non-Cystic Fibrosis Bronchiectasis Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment
  • 8.2.2. By Diagnosis
  • 8.2.3. By End use
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment
      • 8.3.1.2.2. By Diagnosis
      • 8.3.1.2.3. By End use
  • 8.3.2. India Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment
      • 8.3.2.2.2. By Diagnosis
      • 8.3.2.2.3. By End use
  • 8.3.3. Japan Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment
      • 8.3.3.2.2. By Diagnosis
      • 8.3.3.2.3. By End use
  • 8.3.4. South Korea Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Treatment
      • 8.3.4.2.2. By Diagnosis
      • 8.3.4.2.3. By End use
  • 8.3.5. Australia Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Treatment
      • 8.3.5.2.2. By Diagnosis
      • 8.3.5.2.3. By End use

9. Middle East & Africa Non-Cystic Fibrosis Bronchiectasis Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment
  • 9.2.2. By Diagnosis
  • 9.2.3. By End use
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment
      • 9.3.1.2.2. By Diagnosis
      • 9.3.1.2.3. By End use
  • 9.3.2. UAE Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment
      • 9.3.2.2.2. By Diagnosis
      • 9.3.2.2.3. By End use
  • 9.3.3. South Africa Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment
      • 9.3.3.2.2. By Diagnosis
      • 9.3.3.2.3. By End use

10. South America Non-Cystic Fibrosis Bronchiectasis Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment
  • 10.2.2. By Diagnosis
  • 10.2.3. By End use
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment
      • 10.3.1.2.2. By Diagnosis
      • 10.3.1.2.3. By End use
  • 10.3.2. Colombia Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment
      • 10.3.2.2.2. By Diagnosis
      • 10.3.2.2.3. By End use
  • 10.3.3. Argentina Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment
      • 10.3.3.2.2. By Diagnosis
      • 10.3.3.2.3. By End use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Non-Cystic Fibrosis Bronchiectasis Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Novartis AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Pfizer Inc.
• 15.3. Bayer AG
• 15.4. Viatris Inc.
• 15.5. Teva Pharmaceutical Industries Ltd.
• 15.6. GSK plc
• 15.7. F. Hoffmann-La Roche Ltd.
• 15.8. Sun Pharmaceutical Industries Ltd.
• 15.9. Aurobindo Pharma Ltd.
• 15.10. Dr. Reddy's Laboratories Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer